Compare Nano Dimension Ltd - ADR (NNDM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs TG Therapeutics Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 24.8× Nano Dimension Ltd - ADR's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and TG Therapeutics Inc for 16 Days on average.
| NNDM | TGTX | |
|---|---|---|
Market Cap | $328.52M | $8.16B |
Volume | 1,160,945 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $2.14 | $59.06 |
52-Week Low | $1.21 | $26.94 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | -$76.33M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.55 with no recent price movement, reflecting a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to report significant net losses, with a -135.18% net income margin. Recent strategic actions include cost-saving initiatives and leadership changes, with the sale of MarkForged expected to close in late 2026. Cash flow remains volatile, with 2025 showing a net cash outflow of $112M.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and asset sales provide some stability. Investment opportunities exist if cost reductions translate to profitability, but risks include ongoing operational losses and competitive pressures in the industrial sector. The stock's low valuation multiples may attract value investors, but sustained profitability is needed for long-term upside.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
